Integrated manufacturing of REciclable multi-material COmposites for the TRANSport sector

Monocarboxylate transporters (MCTs) play a crucial role in cancer metabolism and progression, most notably MCT1 and MCT4. This review explores the heterocyclic and non?heterocyclic arena of MCT inhibitors in the battle against tumorigenesis. Heterocyclic compounds, such as indole, flavonoid, pyrazole, pteridine and coumarin, and non?heterocyclic compounds, including cyanoacetic acid derivatives and N?cyano sulphonamides, have shown promising potential as MCT inhibitors, offering new therapeutic avenues for cancer treatment.Monocarboxylate transporters (MCTs) have gained significant attention in cancer research due to their critical role in tumour metabolism. MCTs are legends for transporting lactate molecules in cancer cells, an oncometabolite and waste product of glycolysis, acting as an indispensable factor of tumour proliferation. Targeting MCTs with inhibitors has emerged as a promising strategy to combat tumorigenesis. This article summarizes the most recent research on MCT inhibitors in preventing carcinogenesis, covering both heterocyclic and non?heterocyclic compounds. Heterocyclic and non?heterocyclic compounds such as pteridine, pyrazole, indole, flavonoids, coumarin derivatives and cyanoacetic acid derivatives have been reported as potent MCT inhibitors. We examine the molecular underpinnings of MCTs in cancer metabolism, the design and synthesis of heterocyclic and non?heterocyclic MCT inhibitors, their impact on tumour cells and the microenvironment and their potential as therapeutic agents. Moreover, we explore the challenges associated with MCT inhibitor development and propose future directions for advancing this field. This write?up aims to provide researchers, scientists and clinicians with a comprehensive understanding of the heterocyclic and non?heterocyclic MCT inhibitors and their potential in combating tumorigenesis.

» Publication Date: 08/09/2023

» More Information

« Go to Technological Watch